Evidence map›Paper›PMID 42402477›Full record

ReviewInternational journal of stroke : official journal of the International Stroke Society2026

Atrial fibrillation detected after stroke: Recent advances and future directions.

Lussiana Folleco-Insuasty, Luis Fernando Roa-Wandurraga, Federico Liberman, Diana Ayan, Rodrigo Bagur, Luciano A Sposato

Abstract readReview
In one paragraph

Review in International journal of stroke : official journal of the International Stroke Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lussiana Folleco-InsuastyNeurology Unit, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogotá, Colombia.
Luis Fernando Roa-WandurragaNeurology Unit, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogotá, Colombia.ORCID 0000-0001-6811-298X
Federico LibermanDepartment of Medicine, Division of Cardiology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Diana AyanDepartment of Medicine, Division of Cardiology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Rodrigo BagurDepartment of Medicine, Division of Cardiology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Luciano A SposatoHeart and Brain Laboratory, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prolonged cardiac monitoring has made atrial fibrillation (AF) an increasingly common diagnosis after ischemic stroke. Applied to all patients with ischemic stroke, prolonged cardiac monitoring would result in over a million new AF diagnoses per year worldwide. Almost 10 years after the conceptual inception of AF detected after stroke (AFDAS), several patterns are now consistent across studies. AFDAS is a distinct, mechanistically heterogeneous entity that differs from AF known before stroke in its risk-factor profile, cardiac comorbidity, and its lower rate of ischemic stroke recurrence. Its detection is determined primarily by the monitoring method and increases with earlier and longer-duration monitoring. AF identified on a standard electrocardiogram behaves as a high-burden arrhythmia, resembling AF known before stroke, and should be distinguished from the low-burden AF detected by prolonged monitoring. Important questions remain unresolved. It is unproven that detecting more AF, or detecting it earlier, reduces recurrent ischemic stroke. The low-burden arrhythmia that monitoring increasingly identifies appears to carry a lower embolic risk than the high-burden AF for which anticoagulation was established. Whether patients with low-burden, monitor-detected AFDAS derive net benefit from anticoagulation, the contribution of neurogenic mechanisms, and the thresholds of AF burden that should guide treatment are undefined. Future trials should be powered for recurrent stroke as the primary endpoint.

Indexed as

Atrial FibrillationStrokeElectrocardiographyHumansRisk FactorsAFDASanticoagulationAtrial fibrillationcardiac monitoringimplantable cardiac monitorischemic stroketransient ischemic attack

Identifiers

PMID42402477
PMCPMC13392223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.